Videos
Press Releases
17 Mar 2022
MSD’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) Regardless of PD-L1 Expression
29 Jun 2021
PRESS RELEASE: European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre Partner to Address Treatment Gap for Stage 2 Melanoma Patients
4 Jun 2021
PRESS RELEASE: Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer
20 Apr 2021
PRESS RELEASE: HSH Prince Albert II cedes Honorary Presidency of the EORTC Research Fund to HRH Princess Dina Mired
Latest Newsletters
News
5 Nov 2024
EORTC SPRINT clinical cancer study receives support from Rising Tide Foundation to reduce the burden for patients
29 Oct 2024
Pink October at EORTC: Over 60 years of impactful breast cancer research
25 Oct 2024
Do regulations and policies undermine the social value of independent academic research?
10 Oct 2024
EORTC Quality of Life Group’s participation to ISOQOL 2024
8 Oct 2024
New Insights into Glioblastoma Treatment for Older Adults Patients
24 Sep 2024
TOPGEAR trial results show no significant benefit of preoperative chemoradiotherapy on long term survival
17 Sep 2024
Breast Cancer Group,Genito-Urinary Cancers Group,Head and Neck Cancer Group,Lung Cancer Group,Melanoma Group,News
New results and forthcoming EORTC trials in prostate cancer, melanoma, head and neck, lung, rare, and breast cancers presented at ESMO 2024
16 Sep 2024
Late Breaking Results from the EORTC 1333/PEACE III phase III trial
10 Sep 2024
EORTC’s presence at ESMO 2024
